Anchor Capital Advisors LLC lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 408,140 shares of the medical equipment provider’s stock after selling 10,452 shares during the period. Zimmer Biomet Holdings makes up about 1.7% of Anchor Capital Advisors LLC’s investment portfolio, making the stock its 8th biggest holding. Anchor Capital Advisors LLC owned about 0.20% of Zimmer Biomet Holdings worth $47,789,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. increased its stake in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after purchasing an additional 33 shares in the last quarter. BB&T Investment Services Inc. bought a new stake in Zimmer Biomet Holdings in the second quarter valued at approximately $144,000. Sandy Spring Bank increased its stake in Zimmer Biomet Holdings by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares in the last quarter. Finally, Grove Bank & Trust increased its stake in Zimmer Biomet Holdings by 346.1% in the second quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 1,021 shares in the last quarter. 85.44% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) is Anchor Capital Advisors LLC’s 8th Largest Position” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/13/zimmer-biomet-holdings-inc-zbh-is-anchor-capital-advisors-llcs-8th-largest-position.html.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down $1.09 during mid-day trading on Monday, reaching $110.75. 973,400 shares of the company’s stock were exchanged, compared to its average volume of 1,366,571. The firm has a market capitalization of $22,390.00, a PE ratio of 13.72, a P/E/G ratio of 1.72 and a beta of 1.17. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.79 EPS. research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on ZBH shares. Morgan Stanley increased their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, July 17th. BidaskClub downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Cantor Fitzgerald set a $137.00 price objective on shares of Zimmer Biomet Holdings and gave the stock a “hold” rating in a research report on Thursday, July 27th. Canaccord Genuity downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $141.00 to $135.00 in a research report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and a consensus target price of $134.00.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.